^
    Back
    Association details:
    Biomarker:POLE mutation
    Cancer:Solid Tumor
    Drug:Bavencio (avelumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor

    Excerpt:
    Meet at least one of the following requirements; A. PD-L1 positive by IHC or B. EBV positive by ISH or C. MSI-H by IHC or D. POLE mutation E. POLD1 mutation
    Trial ID:
    NCT03491345